Wealth Enhancement Advisory Services
RPRX icon

Wealth Enhancement Advisory Services’s Royalty Pharma RPRX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.6M Buy
195,144
+15,256
+8% +$900K 0.02% 708
2026
Q2 		$9.9M Buy
179,888
+141,175
+365% +$7.35M 0.02% 677
2026
Q1 		$1.88M Sell
38,713
-150,333
-80% -$6.58M ﹤0.01% 1424
2025
Q4 		$7.68M Buy
189,046
+165,451
+701% +$6.31M 0.01% 804
2025
Q3 		$852K Buy
23,595
+3,394
+17% +$123K ﹤0.01% 1969
2025
Q2 		$735K Buy
20,201
+3,841
+23% +$127K ﹤0.01% 1931
2025
Q1 		$509K Buy
16,360
+6,700
+69% +$212K ﹤0.01% 2059
2024
Q4 		$246K Buy
+9,660
New +$256K ﹤0.01% 2538
2024
Q2 		– Sell
-7,197
Closed -$219K – 2690
2024
Q1 		$219K Buy
+7,197
New +$212K ﹤0.01% 2132

Other funds holding RPRX

Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Royal London Asset Management
Royal London Asset Management United Kingdom $54.5B AUM 31.87% 1-Year Est. Return

Wealth Enhancement Advisory Services's RPRX Position: Q3 2026 in Review

Wealth Enhancement Advisory Services increased its Royalty Pharma (RPRX) stake by 8.5% in Q3 2026, buying an estimated $900K and bringing the position to 195,144 shares worth $10.6M. The position accounts for 0.02% of the portfolio, ranked #708.

Wealth Enhancement Advisory Services first reported a position in RPRX in Q1 2024 and has held it in 9 quarters since. 485 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Wealth Enhancement Advisory Services held 195,144 shares of Royalty Pharma worth $10.6M as of Q3 2026.
  • Wealth Enhancement Advisory Services bought 15,256 Royalty Pharma shares in Q3 2026, an estimated $900K.
  • Royalty Pharma made up 0.02% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #708 holding.
  • Wealth Enhancement Advisory Services first reported a position in Royalty Pharma in Q1 2024 and has held it in 9 quarters since.
  • 485 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.